← Pulse/Companies

Flare Therapeutics on Pulse

Biotech

The full thread of our Flare Therapeutics coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jun 30, 2026
Since

Coverage Timeline

newest first
  1. FUNDINGBiotech VCs Are Betting Big on Single Clinical Trials→
  2. FUNDINGFlare Therapeutics Raises $85M, Names New CEO→

All Coverage

FUNDING$391M+ combined across 3 single-trial bets

Biotech VCs Are Betting Big on Single Clinical Trials

Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.

Jul 5, 2026
FUNDING$85M Series C

Flare Therapeutics Raises $85M, Names New CEO

Flare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.

Jun 30, 2026